Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6109259 | 0.95 | F10 (1.00) | F10F2 | |
| Trifluoroacetic Acid SCHEMBL6105097 | 0.95 | F10 (0.91) | F10F2 | |
| SCHEMBL6107432 | 0.90 | F10 (1.00) | F10F2 | |
| Trifluoroacetic Acid SCHEMBL2001149 | 0.82 | F10 (0.89) | F10F2 | |
| Trifluoroacetic Acid SCHEMBL2002425 | 0.81 | F10 (0.90) | F10F2 | |
| Trifluoroacetic Acid SCHEMBL6495496 | 0.78 | F10 (0.91) | F10F2 | |
| Trifluoroacetic Acid SCHEMBL6502964 | 0.77 | F10 (0.92) | F10F2 | |
| SCHEMBL2001820 | 0.76 | F10 (0.98) | F10F2 | |
| SCHEMBL1998289 | 0.75 | F10 (1.00) | F10F2 | |
| SCHEMBL6494300 | 0.72 | F10 (1.00) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115627-B2 | Glycinamides as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-03 | — | — | US | disclosed |
| US-20030232804-A1 | Glycinamides as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232804-A1 | Glycinamides as factor Xa inhibitors | F11, F13B, F12 | F10 5/4885F2 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.